Published on
November 19, 2024
- 13:00 GMT
MyoGene Granted Orphan Drug Designation and Rare Pediatric Disease Designation for Duchenne Muscular Dystrophy Program
These designations make MyoDys45-55, a gene editing therapy designed to treat up to 50% of all Duchenne patients, eligible for incentives SAN DIEGO, CA, UNITED STATES, November 19, 2024 /EINPresswire.com/ -- MyoGene Bio, a biotech dedicated to …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
